PHENAZOPYRIDINE HYDROCHLORIDE- phenazopyridine hydrochloride tablet Northwind Pharmaceuticals

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Indications and Usage

Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled.

The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after 2 days.

Contraindications

Phenazopyridine HCl should not be used in patients who have previously exhibited hypersensitivity to it. The use of Phenazopyridine HCl is contraindicated in patients with renal insufficiency.

Adverse Reactions

Headache, rash, pruritus and occasional gastrointestinal disturbance. An anaphylactoid-like reaction has been described. Methemoglobinemia, hemolytic anemia, renal and hepatic toxicity have been reported, usually at overdosage levels

Precautions

General: A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind.

NOTE: Patients should be informed that Phenazopyridine HCl produces a reddish-orange discoloration of the urine and may stain fabric. Staining of contact lenses has been reported.

Laboratory Test Interaction: Due to its properties as an azo dye, Phenazopyridine HCl may interfere with urinalysis based on spectrometry or color reactions.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term administration of Phenazopyridine HCl has induced neoplasia in rats (large intestine) and mice (liver).

Although no association between Phenazopyridine HCl and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted.

Pregnancy Category B: Reproduction studies have been performed in rats at doses up to

50 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Phenazopyridine HCl. There are, however, no adequate and well controlled studies in pregnant women.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing mothers: No information is available on the appearance of Phenazopyridine HCl, or its metabolites in human milk.

Dosage and Administration


200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.

When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.

Overdosage

Exceeding the recommended dose in patients with good renal function or administering the usual dose to patients with impaired renal function (common in elderly patients) may lead to increased serum levels and toxic reactions. Methemoglobinemia generally follows a massive, acute overdose. Methylene blue, 1 to 2 mg/kg/body weight intravenously or ascorbic acid 100 to 200 mg given orally should cause prompt reduction of the methemoglobinemia and disappearance of the cyanosis which is an aid in diagnosis. Oxidative Heinz body hemolytic anemia may also occur, and "bite cells" (degmacytes) may be present in a chronic overdosage situation. Red blood cell G-6-PD deficiency may predispose to hemolysis. Renal and hepatic impairment and occasional failure, usually due to hypersensitivity, may also occur.

Label Display



PHENAZOPYRIDINE HYDROCHLORIDE

phenazopyridine hydrochloride tablet

Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:51655-154(NDC:65162-520)		
Route of Administration	Oral				

	Ingredient Name			Basis	Basis of Strength S		
PHENAZO PYRIDINE HYDRO CHLO RIDE (UNII: 0EWG668W17) (UNII:K2J09EMJ52)			PHENAZOPYRIDIN		PHENAZOPYRIDINE HYDROCHLORIDE 200 m		
Product Characteri	ation						
Color	brown	Score			no scor	no score	
Shape	ROUND	Size			10 mm	10 mm	
-			Imprint Code		AN;2		
Flavor		Imprint	t Code		AN;2		
Flavor Contains		Imprint	t Code		AIN;2		
		Imprint	Code		AN;2		
Contains	Package Des		Code Marketing S	Start Date		ting End Date	
Contains Packaging	Package Des 6 in 1 BOTTLE, DISP	scription		Start Date		ting End Date	
Contains Packaging # Item Code	-	scription		Start Date		ting End Date	
Contains Packaging # Item Code 1 NDC:51655-154-87	6 in 1 BOTTLE, DISP	scription		Start Date		ting End Date	
Contains Packaging # Item Code	6 in 1 BOTTLE, DISP	scription ENSING	Marketing S	Start Date rketing Start I	Marke	ting End Date rketing End Date	

Labeler - Northwind Pharmaceuticals (036986393)

Registrant - Northwind Pharmaceuticals (036986393)

Establishment

Name	Address	ID/FEI	Business Operations
EPM Packaging		079124340	repack(51655-154)

Revised: 6/2014

Northwind Pharmaceuticals